SSY GROUP (02005) obtained the drug production registration approval for Tartro Tero extended-release capsules (4mg).

12:03 28/11/2025

ShiSiYao Group (02005) announced that the group has obtained the drug production registration approval from the National Medical Products Administration of China for the tartaric acid tolterodine sustained-release capsules (4mg). It belongs to the fourth class of chemical drugs, considered equivalent by consistency evaluation, and is the third domestic company to receive approval. Tartaric acid tolterodine sustained-release capsules are mainly used to treat overactive bladder syndrome.

The SSY Group (02005) announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for Tartaric Acid Tolterodine Sustained Release Capsules (4mg), which belongs to the category 4 of chemical drugs. The approval was granted through a consistency evaluation, making the group the third domestic company to receive approval. Tartaric Acid Tolterodine Sustained Release Capsules are mainly used for the treatment of overactive bladder syndrome.

JINHUI HOLDINGS(00137): Jinhui Shipping's net profit for the third quarter was $82,000, a decrease of 98.92% year-on-year.

China Water (00855) will distribute an interim dividend of 13 Hong Kong cents per share on June 18, 2026.

CHINA WATER (00855) achieved a mid-year profit of about HK$5.183 billion, with a dividend of 13 HK cents per share.

JINHUI HOLDINGS(00137): Jinhui Shipping's net profit for the third quarter was $82,000, a decrease of 98.92% year-on-year.

China Water (00855) will distribute an interim dividend of 13 Hong Kong cents per share on June 18, 2026.

CHINA WATER (00855) achieved a mid-year profit of about HK$5.183 billion, with a dividend of 13 HK cents per share.